BioSpace News Archive

Policy

FDA Places New CMC Demands on bluebird’s Sickle Cell Treatment

The company announced late Wednesday that its sickle cell disease gene therapy treatment will not be submitted to the U.S. Food and Drug Administration for two more years.

November 5, 2020
·
2 min read
·
Alex Keown
Business

Top 25 Women Leaders in Biotech: Female Execs Paving the Way for Innovation

The Healthcare Technology Report announced on Nov. 3 its list of the Top 25 Women Leaders in Biotechnology of 2020.

November 5, 2020
·
2 min read
·
Krystle Vermes
Q3 Reports: AbbVie, BMS, Allogene, Gilead and AstraZeneca

It’s a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.

November 5, 2020
·
6 min read
·
Mark Terry
Potential MS Therapy Shows Promising Efficacy, Avoids Immune Suppression

Researchers from the Thomas Jefferson University have designed an antigen-specific therapy for the autoimmune disease multiple sclerosis (MS) using oligodendrocyte-derived extracellular vesicles.

November 5, 2020
·
3 min read
·
Brandon May
Business

Bringing Flexion’s OA Gene Therapy to Market Starts with Cost and Benefits in Mind

As more and more gene therapies are approved, the elements that determine their success depend, increasingly, on the business decisions made early on.

November 5, 2020
·
4 min read
·
Gail Dutton
Career Advice

The Do’s and Don’ts to Remember When Writing a Professional Email

Oh, the world of professional email communication. It can be hard to navigate with various expectations across industries, age groups and cultures.

November 5, 2020
·
3 min read
·
Laura Brothers
Business

SPACs Soar as Fast, Hassle-Free IPO Alternatives for Biotech Companies

Special purpose acquisition companies (SPACs) are resurging as a virtually hassle-free alternative to initial public offerings (IPOs). They’ve been around for years, but are just now becoming a factor for biotech.

November 5, 2020
·
4 min read
·
Gail Dutton
Business

Can Pharma Win Back America?

According to recent polls, less than half of Americans trust pharmaceutical companies. In fact, only 42% of respondents say they have any trust in pharma, with a paltry 6% having a great deal.

November 5, 2020
·
4 min read
·
Kate Goodwin
Drug Development

Allogene’s Off-the-Shelf Myeloma CAR-T Data Marred by Patient Death

South San Francisco-based Allogene Therapeutics released some early data from its Phase I UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.

November 5, 2020
·
3 min read
·
Mark Terry
Deals

Merck Snaps Up VelosBio and its ROR1 Inhibitor in $2.75 Billion Deal

Merck is dropping $2.75 billion to acquire a promising cancer therapy that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors.

November 5, 2020
·
3 min read
·
Alex Keown